2024 ADHD Review: Quality of Life & Outlook

Nature Reviews Disease Primers published a 2024 review on ADHD. B/c only the abstract is publically available, here are points of possible interest.

Quality of Life: “ADHD negatively affects various functional areas throughout development, which can often lead to a negative self-perception…considering the cultural and value systems to
which that individual belongs
.”

“In youths, ADHD can lead to educational and occupational failure, peer conflicts and social exclusion, family conflict, teenage pregnancy and sexually transmitted diseases.” “These impairments accumulate over time, reducing self-esteem and wellbeing and increasing the risks of suicidality.”

“In adults, ADHD impairs work functioning, relationship quality, financial stability and parenting skills. These issues can affect QoL, which is further reduced with the continued risk of accidents and the emergence of adverse medical outcomes such as cardiometabolic disease. Naturalistic studies have shown that medications improve many functional outcomes, reduce motor vehicle crashes, lower the risk of substance use, lead to higher educational achievement and reduce mortality and premature death.”

Outlook: “We need to learn more about the extent and effect of stigma on people with ADHD, and to improve strategies to avoid stigma.”

“Studies of mechanisms and pathophysiology have reached a turning point. Large collaborative studies have yielded clear evidence about the effect of genetic variants on ADHD and we are beginning to
understand the subtle brain differences between individuals with and those without ADHD.”

“Although we know much about the impairments…much less is known about potential assets and strengths associated with the disorder.”

“Lifestyle recommendations will become a component of multimodal treatment programmes for ADHD along with medication and behavioural interventions. We will see studies of neurotherapies,
applications, wearables, gaming platforms and other digital tools aiming to reduce symptoms of ADHD and monitor symptoms during treatment.”

“Future work on ADHD will be influenced by the neurodiversity framework that considers ADHD to be associated with…brain development and cognitive style” differences “rather than being a disorder per se.”

2024 ADHD Review: “Interventions”

Nature Reviews Disease Primers published a 2024 review on ADHD. B/c only the abstract is publically available, here are points of possible interest.

Medication: “Pharmacotherapy is considered the first-line treatment for ADHD (after implementation
of environmental modifications
).” And yet environmental modifications are so often overlooked!! Even the article says little about them, though it says, “In some patients, assessment of neurocognitive functions may detect cognitive strengths and weaknesses…helpful for planning educational or
vocational strategies.” I’d add that these strategies could include environmental modifications.

FDA-approved medications for ADHD are stimulants (methylphenidate and amphetamine
formulations) and non-stimulants. “Clinical guidelines recommend stimulants as the first-choice medication for ADHD owing to their high efficacy.”

“Some patients have an excellent response to non-stimulant monotherapy, whereas others are optimally treated with combinations of stimulants and non-stimulants, or combinations of longer-acting and shorter-acting stimulants.”

“No clinical or biological predictors of response are available for ADHD. Finding the optimal medication relies on educated trial-and-error. Identifying the optimal dose of stimulants may require several
weeks, with weekly titration.”

Most common adverse side effects are “appetite reduction, delayed sleep onset (stimulants) and other sleep issues (non-stimulants), although patients can also experience” better sleep due to decreased evening hyperactivity.

With ADHD, “There are no guidelines as to how” a medication “should be continued and how or when it should be stopped.”

Psychosocial (Adolescents & Children): “Behavioural therapy and cognitive–behavioural therapy (CBT)” are primary here. “These therapies are typically multicomponent, engage parents and modify behaviours based on social learning principles and cognitive–behavioural strategies (organization skills, problem solving, metacognitive strategies and social skills).” These therapies seek to temper the effect of ADHD …by modifying environmental factors (for example, parenting and educational context) and psychological factors (for example, psychological beliefs and coping mechanisms)

“Compared with medication, behavioural therapy puts higher demands on parents, patients and clinicians. Moreover, behavioural therapy takes longer to show initial efficacy than pharmacological therapy, because many weeks of therapy are needed. Behavioural therapy is well-liked by patients and consistently shows maintenance effects for months and sometimes years,” especially for adolescents.

Psychosocial (Adults): CBT (individual or group)…”as well as skills training have the greatest
evidence for efficacy.” “CBT aims to change dysfunctional thoughts and behaviours. Skills training addresses problem solving, distraction delay techniques, time management, behavioural control instructions, emotion regulation, mindfulness and social communication.”

Randomized controlled trials “show that combined treatment with medication and CBT is superior to medication alone for ADHD symptoms. CBT alone also improves anxiety, depression, self-esteem and emotional regulation.” In adults, “behavioural therapies can have long-lasting effects.”

Nutrition & Exercise: “ADHD is associated with unhealthy diets…high intake of ultra-processed foods with high proportions of refined sugar and saturated fat, and nutritional deficiencies, such as of vitamins B2 and B6 and polyunsaturated fatty acids. Importantly, however, these findings are observational rather than causal, because ADHD symptoms and the genetic risk of ADHD may influence dietary choices.”

“Significant although small to moderate reductions…ADHD symptoms based on properly blinded and controlled RCTs have been reported for ω3 fatty acid supplements, broad-spectrum micronutrient supplements, and exclusion of food colour additives and preservatives.”

“Complex interventions with healthy diets, a Mediterranean diet and the Dietary Approach to Stop Hypertension offer promise but await rigorous testing. Similarly, physical exercise may briefly relieve ADHD symptoms but has limited efficacy.”

Neurotherapy: “Trigeminal nerve stimulation (TNS) is an FDA-approved treatment for ADHD” based on an RCT with 62 child participants. A medium effect size was found “after 4 weeks of nightly TNS applications.”

2024 ADHD Review: Diagnosis & Screening

Nature Reviews Disease Primers published a 2024 review on ADHD. B/c only the abstract is publically available, here are points of possible interest.

Diagnosis and Screening: Dx “must be based on an interview of the parent and/or patient. No biological measure of ADHD shows sufficient sensitivity and specificity to serve as a standalone diagnostic test.”

Diagnosis & Screening, Assessment of kids & teens: The researchers emphasize reliance on questionnaires, particularly answered by teachers, parents and, with teens, the teens themselves. They include a list of “Free Tools” (if one goes to the article online, to “supplementary information”). I pasted the list here, which includes measures that go beyond ADHD.

Clinical Interviews: KSADS DSM 5 Developmental Epidemiology Instruments Developmental and Wellbeing Assessment (U.K.) Parent Interview for Child Symptoms

Rating Scales: Vanderbilt ADHD Rating Scales SNAP IV (full) SNAP IV (short) Strengths and Difficulties Questionnaire

Diagnosis & Screening, Assessment of adults: The authors note, given questions about adult-onset ADHD, that although some studies indicate adult-onset ADHD may occur, “limitations of these studies and subsequent research indicate that” it mostly starts during childhood or adolescence. It simply may be identified late. The authors also note that “misinformation” on social media confuses people, leading to thoughts they have ADHD when something else may be occurring.

Clinical Interview: Diagnostic Interview for Adult ADHD, (DIVA-5)

Rating Scales: Adult ADHD Self-Report Scale (ASRS-5) Wender Utah Rating Scale (WURS) WURS-25

2024 ADHD Review: Epidemiology to Enviro

Nature Reviews Disease Primers published a 2024 review on ADHD. B/c only the abstract is publically available, here are points of possible interest.

Introduction: “…we know the disorder’s core symptoms (inattention, hyperactivity and impulsivity), impairments (for example, school and occupational failure, poor socialization, and accidental injuries) and comorbidities (for example, anxiety and mood disorders).

Epidemiology (distribution and determinants): “In school-aged children, the prevalence of ADHD based on epidemiological samples representative of the general population is 5.3%…. In some individuals, symptom severity declines during adolescence but two-thirds of children…retain impairing symptoms…. In early adulthood, the prevalence of ADHD is ~2.5% with a gradual decrease to 1% at older ages.

“Only 56.8% of individuals with ADHD are diagnosed before 14…73.0% are diagnosed by 18 years and 91.8% by 25 years.”

“ADHD symptoms and impairments tend to worsen under certain conditions…increased self-regulation challenges, weak support systems, intensification of comorbid conditions and poor fit between individuals and their environment.”

Co-travelers: “ADHD often coexists with other psychiatric disorders.” “ADHD is also often comorbid with somatic conditions.” In children, these somatic conditions are dermatitis, obesity, asthma and rhinitis. In adults, this includes type 2 diabetes mellitus. ” “ADHD is also associated with vision problems….” “Children with ADHD have many sleep difficulties, including bedtime resistance, late sleep onset, night awakenings, morning awakenings, sleep disordered breathing and daytime sleepiness.”

Mechanisms/Pathophysiology, Genetics: “Meta-analyses…have shown…heritability of ADHD is ~80%.”

“[S}hared genetic factors partly explain the co-occurrence of ADHD with other psychiatric disorders …anxiety, major depressive, bipolar, conduct, autism spectrum and substance use disorders…and some somatic conditions. …ADHD is genetically associated with measures of cognition, electroencephalographic (EEG) variability and subtle structural brain differences.”

“The largest genome-wide association studies (GWAS) of ADHD found 27 genome-wide significant loci implicating 76 genes, many…upregulated during early brain development.” (upregulated: increased expression/activation) “ADHD genetic risk is enriched for genes associated with several brain-specific neuronal subtypes and midbrain dopaminergic neurons.”

Mechanisms/Pathophysiology, Environmental Correlates: “…strong evidence that rare events…traumatic brain injury…extreme emotional…nutritional deprivation…can cause ADHD….” “[M]any other environmental events are associated with ADHD. Most…events or complications…during pregnancy, delivery or early after birth (for example, low birthweight, perinatal hypoxia and advanced paternal age), although all have low risk ratios for ADHD.

Electrophysiology and brain imaging: “The most recent mega-analysis included five cohorts with almost 7,000 participants, and found reduced fractional anisotropy.” Where? The “inferior longitudinal and left uncinate fasciculi.” (The UF connects the temporal lobe with the medial orbitofrontal cortex, per articles cited here. Animal studies show its disconnection “causes impairment of object-reward association learning” and reduced memory performance “involving temporally complex visual information.” Studies on neurodevelopmental and neurological disorders show UF damage correlates with emotional processing deficits, “behavioral inhibition…and impaired object naming….

In meta-analyses of fMRI studies of cognitive control, the most consistent finding “is under-activation of the inferior frontal cortex (IFC) and the insula” among people with ADHD compared to controls.

Blog at WordPress.com.

Up ↑